# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2191-2200 of 2216 results.
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Status: Unknown status
Last Changed: Mar 10, 2017
First Received: Mar 10, 2017
Disease(s): Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Intervention(s): Drugs and Anti-CD19-CAR transduced T cells
Locations: Department of Hematology, Dongguan People's Hospital, Dongguan, Guangdong, China
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
Status: Terminated
Last Changed: Sep 24, 2012
First Received: May 07, 2003
Disease(s): Lymphoma
Intervention(s): CHOP regimen, EPOCH regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy
Locations: U.Z. Gasthuisberg, Leuven, Belgium
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Status: Unknown status
Last Changed: Aug 03, 2016
First Received: May 28, 2015
Disease(s): Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Lymphoma
Intervention(s): Fludarabine, Cyclophosphamide, Anti-CD19-CAR transduced T cells
Locations: Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China
Study of Cemiplimab and REGN1979 in Patients With Lymphoma
Status: Active, not recruiting
Last Changed: Aug 04, 2020
First Received: Jan 11, 2016
Disease(s): Lymphoma
Intervention(s): cemiplimab, REGN1979
Locations: Regeneron Research Facility, Santa Monica, California, United States
Regeneron Research Facility, Baltimore, Maryland, United States
Regeneron Research Facility, Boston, Massachusetts, United States
Regeneron Research Facility, Grand Rapids, Michigan, United States
Regeneron Research Facility, Lebanon, New Hampshire, United States
... and 14 other locations.
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Status: Completed
Last Changed: Mar 07, 2016
First Received: Apr 06, 2005
Disease(s): Lymphoma
Intervention(s): rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
Locations: Alaska Regional Hospital Cancer Center, Anchorage, Alaska, United States
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Piedmont Hospital, Atlanta, Georgia, United States
Northside Hospital Cancer Center, Atlanta, Georgia, United States
... and 74 other locations.
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Status: Recruiting
Last Changed: Jan 18, 2020
First Received: Jan 30, 2014
Disease(s): Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
Intervention(s): CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
Locations: Houston Methodist Hospital, Houston, Texas, United States
Texas Children's Hospital, Houston, Texas, United States
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Status: Recruiting
Last Changed: Sep 16, 2020
First Received: Sep 19, 2018
Disease(s): Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA
Intervention(s): inotuzumab ozogamicin-dose level 2, Inotuzumab ozogamicin-dose level 1
Locations: Keck Hospital of USC-Norris Comprehensive Cancer Center (HC3), Los Angeles, California, United States
Keck Hospital of USC, Los Angeles, California, United States
LAC+USC Medical Center, Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Children's Hospital of Orange County, Orange, California, United States
... and 62 other locations.
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
Status: Completed
Last Changed: Jun 25, 2013
First Received: Jan 27, 2003
Disease(s): Leukemia, Lymphoma
Intervention(s): filgrastim, rituximab, cyclophosphamide, pentostatin
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Completed
Last Changed: May 27, 2013
First Received: Apr 01, 2009
Disease(s): Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Intervention(s): perifosine
Locations: Duke University Medical Center, Durham, North Carolina, United States
Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status: Terminated
Last Changed: Jul 09, 2015
First Received: May 20, 2009
Disease(s): Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Acute Lymphoblastic Leukemia
Intervention(s): Nilotinib